Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Midazolam oral solution ED90 for preoperative sedation in pediatric left-to-right shunt congenital heart disease
ChiCTR2500111281Phase 4Not yet recruiting
- Sponsor
- Children's Hospital of Chongqing Medical University
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of midazolam in atrial septal defect (ASD), Ventricular Septal Defect (VSD), patent ductus arteriosus (PDA) and 1 more (3 arms), sponsored by Children's Hospital of Chongqing Medical University. Primary endpoints: Calming effect (MOAA/S), Calming effect (Mask Acceptance Scale) and 1 more. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
midazolam
03
Conditions
atrial septal defect (ASD)Ventricular Septal Defect (VSD)patent ductus arteriosus (PDA)Cardiovascular Malformation (CVM)
Beyond the preview
Go deeper on ChiCTR2500111281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500111281.